13 terminated. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 13 |
| Phase 2 | 2 | Terminated 2 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age VX-659/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Terminated | Vertex Pharmaceuticals Incorporated | 18 | 2018-08-03 | 2020-02-05 |
| A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy VX-659/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Terminated | Vertex Pharmaceuticals Incorporated | 484 | 2018-07-13 | 2022-01-25 |
| Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria AZLI, Placebo - Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis | Phase 3 | Terminated | Gilead Sciences | 149 | 2017-11-28 | 2022-06-14 |
| Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis Tobi Inhalant Product, Nebcin - Cystic Fibrosis | Phase 3 | Terminated | University Hospital, Lille | 23 | 2017-06-13 | 2021-09-05 |
| Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients Tobramycin nebulized nasally, Physiologic serum nebulized nasally - Cystic Fibrosis, Rhinosinusitis | Phase 3 | Terminated | Virginie ESCABASSE | 86 | 2017-02-16 | 2023-02-15 |
| A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation ivacaftor, Placebo - Cystic Fibrosis | Phase 3 | Terminated | Vertex Pharmaceuticals Incorporated | 14 | 2016-05-01 | 2018-11-19 |
| Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis Ataluren - Cystic Fibrosis | Phase 3 | Terminated | PTC Therapeutics | 246 | 2015-08-31 | 2020-04-27 |
| The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients novolog insulin, levemir insulin, placebo - Cystic Fibrosis | Phase 2 / Phase 3 | Terminated | University of Minnesota | 65 | 2015-08-01 | 2025-03-17 |
| Study of Ataluren (PTC124) in Cystic Fibrosis Ataluren - Cystic Fibrosis | Phase 3 | Terminated | PTC Therapeutics | 61 | 2014-05-23 | 2020-03-25 |
| Prevention of Cystic Fibrosis Diabetes Sitagliptin - Cystic Fibrosis, Prediabetes | Phase 3 | Terminated | Emory University | 33 | 2010-05-01 | 2018-06-25 |
| Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) Denufosol tetrasodium Inhalation Solution - Cystic Fibrosis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 308 | 2009-02-01 | 2015-11-06 |
| Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects Tobramycin Inhalation Powder - Cystic Fibrosis | Phase 3 | Terminated | Novartis | 98 | 2005-09-01 | 2011-10-12 |
| Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis tgAAVCF - Cystic Fibrosis | Phase 2 / Phase 3 | Terminated | Targeted Genetics Corporation | 100 | 2003-06-01 | 2008-01-28 |
Lung Diseases (2) · Diabetes Mellitus (1) · Inflammation (1) · Prediabetic State (1) · Rhinosinusitis (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Digestive System Diseases (13) · Genetic Diseases, Inborn (13) · Infant, Newborn, Diseases (13) · Pancreatic Diseases (13) · Respiratory Tract Diseases (13) · Lung Diseases (11) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Infections (1) · Metabolic Diseases (1) · Nose Diseases (1) · Nutritional and Metabolic Diseases (1) · Otorhinolaryngologic Diseases (1) · Paranasal Sinus Diseases (1)
ivacaftor (3) · Tobramycin (2) · ataluren (2) · Aztreonam (1) · Insulin Aspart (1) · Insulin Detemir (1) · Sitagliptin Phosphate (1) · Sodium Chloride (1)
Vertex Pharmaceuticals Incorporated (3) · PTC Therapeutics (2) · Emory University (1) · Gilead Sciences (1) · Merck Sharp & Dohme LLC (1) · Novartis (1) · Targeted Genetics Corporation (1) · University Hospital, Lille (1) · University of Minnesota (1) · Virginie ESCABASSE (1)
United States (9) · France (5) · Canada (4) · Israel (4) · Spain (4) · United Kingdom (4) · Australia (3) · Belgium (3) · Germany (3) · Italy (3) · Argentina (2) · Brazil (2) · Bulgaria (2) · Denmark (2) · Greece (2)
Joseph McIntosh, MD (2) · Antoinette Moran, MD (1) · Arlene A Stecenko, MD (1) · Lynn Smiley, MD (1) · Virginie Escabasse, MD (1)
PMID 33331662, PMID 37983082, PMID 35390177, PMID 36866921, PMID 37455237
2014 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1)